<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Jaguar-Health-Inc-US47010C3007">Jaguar Health, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Accesswire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 4 Monaten</div>
        <span class="me-2 new badge text-secondary bg-gray-200" data-bs-toggle="tooltip"
              data-bs-title="Automatisch aus dem Englischen übersetzt. Standardsprache in den Einstellungen ändern."
              title="Automatisch aus dem Englischen übersetzt. Standardsprache in den Einstellungen ändern.">EN</span>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/additional-infant-patient-to-receive-jaguar-healths-crofelemer-for-co-1194425">Weiterer Säuglingspatient erhält Jaguar Healths Crofelemer auf Grundlage humanitärer Nutzung zur Behandlung von Dünndarmversagen (IF) infolge von Microvillus‑Inklusionskrankheit (MVID)</a>
    </div>

      <div class="me-0 me-md-5">
        Jaguar bleibt stark fokussiert auf sein laufendes globales Entwicklungsprogramm für orales Crofelemer als ergänzende Therapie zur parenteralen Unterstützung (PS) für seltene IF‑Erkrankungen, einschließlich MVID SAN FRANCISCO, CA / ACCESS Newswire / 22. Juli 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) gab heute bekannt, dass die Jaguar‑Tochtergesellschaft Napo Pharmaceuticals (Napo) das ne...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Jaguar-Health-Inc-US47010C3007">Jaguar Health, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Accesswire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 5 Monaten</div>
        <span class="me-2 new badge text-secondary bg-gray-200" data-bs-toggle="tooltip"
              data-bs-title="Automatisch aus dem Englischen übersetzt. Standardsprache in den Einstellungen ändern."
              title="Automatisch aus dem Englischen übersetzt. Standardsprache in den Einstellungen ändern.">EN</span>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/presentation-at-espghan-2026-describes-additional-groundbreaking-resu-1184345">Präsentation auf der ESPGHAN 2026 beschreibt weitere bahnbrechende Ergebnisse zur Bewertung von Jaguar Healths Crofelemer als adjunctive orale Therapie zur Behandlung von pädiatrischer intestinaler Insuffizienz (IF)</a>
    </div>

      <div class="me-0 me-md-5">
        Das Unternehmen bleibt stark fokussiert auf sein laufendes globales Entwicklungsprogramm für Crofelemer bei seltenen IF-Erkrankungen Kurzfristige Meilensteine für das IF-Programm werden durch anhaltend bahnbrechende Ergebnisse der Studie gestützt, die eine Reduktion der parenteralen Unterstützung normalisiert auf das Körpergewicht von bis zu 48 % bei einem Patienten mit der ultrararen pädiatris...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Jaguar-Health-Inc-US47010C3007">Jaguar Health, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Accesswire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 5 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/jaguar-health-announces-conversion-of-series-o-convertible-preferred-1182061">Jaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock Dividend</a>
    </div>

      <div class="me-0 me-md-5">
        Company remains sharply focused on its ongoing global development program for crofelemer for rare intestinal failure diseases Reminder: Two crofelemer presentations in pediatric intestinal failure patients with microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF) to be conducted at June 2026 Annual European Society for Pediatric Gastroenterology, Hepatology &amp; Nutrition (ESPGHA...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Jaguar-Health-Inc-US47010C3007">Jaguar Health, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Accesswire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 5 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/jaguar-health-completes-submission-of-new-animal-drug-application-for-1180236">Jaguar Health Completes Submission of New Animal Drug Application for Full FDA Approval of Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs</a>
    </div>

      <div class="me-0 me-md-5">
        Jaguar&#39;s recently completed pivotal effectiveness study of crofelemer for the treatment of CID in dogs demonstrates positive, statistically significant results SAN FRANCISCO, CA / ACCESS Newswire / June 23, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (&quot;Jaguar&quot;) today announced that the company has completed submission of its New Animal Drug Application (NADA) to the U.S. Food and Drug Administrati...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Jaguar-Health-Inc-US47010C3007">Jaguar Health, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Accesswire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 5 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/jaguar-health-announces-plan-to-explore-strategic-alternatives-aligne-1179969">Jaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intestinal Failure Program</a>
    </div>

      <div class="me-0 me-md-5">
        Reminder: Lisa Conte, Jaguar&#39;s founder &amp; CEO, to present on June 24, 2026 at the Life Sciences Virtual Investor Forum to provide updates on company&#39;s crofelemer development program for rare intestinal failure diseases; click here to register SAN FRANCISCO, CA / ACCESS Newswire / June 22, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (&quot;Jaguar&quot; or the &quot;Company&quot;) today announced that its Board of Direc...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Jaguar-Health-Inc-US47010C3007">Jaguar Health, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Accesswire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 5 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/magdalena-biosciences-a-joint-venture-between-jaguar-health-and-filam-1178383">Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Announces Positive Results of Preclinical Study of Coca for Weight Gain Prevention</a>
    </div>

      <div class="me-0 me-md-5">
        Whole leaf coca extract under evaluation is Magdalena&#39;s drug candidate for post-GLP-1 weight loss management SAN FRANCISCO, CA / ACCESS Newswire / June 18, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (&quot;Jaguar&quot;) today announced that the results of a preclinical study initiated by Magdalena Biosciences (&quot;Magdalena&quot;), a US-based joint venture formed by Jaguar and Canada-based Filament Health Corp. (&quot;...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Jaguar-Health-Inc-US47010C3007">Jaguar Health, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Accesswire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 5 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/jaguar-health-presenting-june-24-2026-at-the-life-sciences-virtual-in-1176431">Jaguar Health Presenting June 24, 2026 at the Life Sciences Virtual Investor Forum to Provide Updates on Company&#39;s Crofelemer Development Program for Rare Intestinal Failure Diseases</a>
    </div>

      <div class="me-0 me-md-5">
        Click here to register for event To access the replay of the June 10, 2026 presentation by Lisa Conte, Jaguar&#39;s founder, president &amp; CEO, at the Emerging Growth Conference, click here Reminder: Two crofelemer presentations in pediatric intestinal failure patients with microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF) to be conducted at June 24-27, 2026 Annual European Socie...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Jaguar-Health-Inc-US47010C3007">Jaguar Health, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Accesswire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 5 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/jaguar-health-reports-approval-of-all-proposals-at-2026-annual-meetin-1173894">Jaguar Health Reports Approval of All Proposals at 2026 Annual Meeting of Stockholders</a>
    </div>

      <div class="me-0 me-md-5">
        Lisa Conte, Jaguar&#39;s founder, president &amp; CEO, presenting virtually on June 10, 2026 at the Emerging Growth Conference; click here to register SAN FRANCISCO, CA / ACCESS Newswire / June 8, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (&quot;Jaguar&quot; or the &quot;Company&quot;) today announced the voting results of the Company&#39;s May 22, 2026 Annual Meeting of Stockholders (the &quot;Annual Meeting&quot;), which was adjourned...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/news/Jaguar-Health-Inc-US47010C3007/load_more?page=4">
      Mehr Neuigkeiten anzeigen
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>